• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

Is the Time Right to Buy Amgen After the Horizon Therapeutics Deal?

Here's the play traders can make.
By STEPHEN GUILFOYLE
Dec 12, 2022 | 10:30 AM EST
Stocks quotes in this article: HZNP, AMGN, WFC, SNY, JNJ

Horizon Therapeutics (HZNP) closed on Friday at $97.29, which works out to 20.5 times forward looking earnings. For Horizon's third quarter, the firm posted GAAP and adjusted EPS that beat Wall Street on about $925M in revenue. While that number did beat expectations, it actually accounted for a year over year sales contraction of 11%. Though overall sales had increased 47% last year over the year prior.

However, this has not stopped others from showing interest in the Ireland-based firm that focuses on rare and rheumatic diseases.

On Monday morning, news broke that Amgen (AMGN) had agreed to acquire Horizon for $116.50 per share, which is a 20% premium to Friday's closing price. The shares were trading in the low $60's when it started to become obvious that Horizon was in play. Interestingly, in late November, Wells Fargo (WFC) analyst Derek Archila had come up with a "back of the envelope" valuation of $135 per share as fair value. If so, it would appear that Amgen has done well in this deal.

The deal values the firm's fully diluted equity at about $27.8B or $28.3B when debt is included. The deal came about after both Sanofi (SNY) and the Janssen Global Services unit of Johnson & Johnson (JNJ) had backed off.

Horizon has three leading revenue producing products, Tepezza, Krystexxa, and Uplizna. The three therapeutics have in aggregate... added about $2B to the firm's sales totals through the first nine months of the fiscal year. The one with the highest ceiling is thought to be Tepezza, which is used to treat thyroid eye disease. This product is projected to potentially hit $4B in annual sales at its apex.

Amgen expects to use cash in hand and debt to finance this deal, which is expected to close at some point during H1 2023. The merger becomes accretive to revenue and adjusted earnings as soon as 2024. Amgen has not (yet?) updated prior guidance.

Amgen

Amgen reported the firm's third quarter in early November. Beats on the top and adjusted bottom lines. Revenue "grew" -0.9% year over year and has not experienced sales growth of more than 6% since Q3 2020. Amgen has posted many successive quarters of positive free cash flow, including $2.8B worth for the most recent quarter and $9.3B for the trailing 12 months. Amgen ended the last quarter with a net cash position of $11.478B and a current ratio of 1.68. This is all good.

However, Amgen also already has $37.161B worth of long-term debt on the books and another $1.5B in debt labeled as current. Now, they will reduce the cash position and increase the debt-load in order to bring on Horizon that upon acquisition will tack on another $2.5B worth of long-term debt. I do understand having to import growth once growth becomes stagnant, and Horizon's existing business certainly appears likely to grow. That said, I do not like the size of Amgen's current debt-load, nor the acknowledgement that it will grow as the cash on hand is spent. There is some risk here.

Amgen's stock trades at 17 times forward looking earnings, and currently pays out $7.76 annually to shareholders per share, yielding 2.78%, which is nice. The free cash flow has been beefy. I would like to hear out loud that the dividend is safe. Can they do that? I don't know.

Thoughts

Amgen is expected to report late in January. Wall Street is looking for adjusted EPS of $4.08, GAAP EPS of $3.06 and revenue of $6.77B. At consensus, that's negative earnings growth on negative sales growth. Horizon will report in mid to late February. Wall Street sees adjusted EPS of $1.09, GAAP EPS of $0.57 and revenue of $923M there. Negative earnings growth on negative sales growth here too.

I have to say, despite Wells Fargo's opinion, I am not sure that this deal makes an immediate improvement to Amgen's situation, but it will likely have a corrosive impact upon the quality of the balance sheet.

AMGN comes in having already broken out from a flat base that ran from April through September. I see the probability that the stock retraces a portion of that move as likely even if there was not a large deal afoot.

I do not see this morning's dip in the AMGN share price as an opportunity for medium to long-term investors. Traders however, can play a move back to the 50 day SMA, or try to arb the $111 last sale for HZNP against the take out price. Some point in H1 2023 might seem like a while for one trying to make $5.

I have noticed that I have not seen anything from the community of sell-side analysts on this deal from Amgen's perspective. Sometimes, the prudent thing is to put one's hands in one's pockets.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was Long WFC equity.

TAGS: Mergers and Acquisitions | Dividends | Drug Approvals | Investing | Stocks | Technical Analysis | Trading | Healthcare

More from Investing

The Market Is Embracing a Goldilocks Scenario for Now

James "Rev Shark" DePorre
Jan 27, 2023 6:34 AM EST

The belief is that inflation isn't too hot and economic growth isn't too cold, though the bears argue this view is unrealistic.

Nvidia's Ready to Move, So Don't Get Left in the Ray-Traced Shadow

Ed Ponsi
Jan 27, 2023 6:00 AM EST

Here why this tech name should be back on your radar -- and why you should question downer economic forecasts.

Chevron Is Not Only Greasing the Wheels, It's Turbocharging Them

Jim Collins
Jan 26, 2023 5:07 PM EST

Let's look at why CVX's buyback news is a big deal for investors.

Traders Hold Their Noses and Buy

James "Rev Shark" DePorre
Jan 26, 2023 4:27 PM EST

The dull market got a boost from Tesla, but this is not the kind of action we want to see.

Phillips 66 Looks Like It's on the Right Route

Bruce Kamich
Jan 26, 2023 1:33 PM EST

PSX appears poised for further gains as earnings approach, according to the charts and indicators.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 03:06 PM EST BOB LANG

    LEAPS Webinar

    This week, I offered a free webinar session talkin...
  • 02:53 PM EST REAL MONEY

    LIVE EVENT: Chris Versace and "Sarge" Guilfoyle Share Their Stock Market Insights

    This Monday, Jan. 30, at 12 p.m., our very own exp...
  • 04:58 PM EST REAL MONEY

    The Latest AAP Podcast!

    Listen in as AAP Tackles Earnings, the Fed, Recess...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login